Literature DB >> 23321332

Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension.

Chia-Hung Yen1, Tzu-Hsien Tsai, Steve Leu, Yung-Lung Chen, Li-Teh Chang, Han-Tan Chai, Sheng-Ying Chung, Sarah Chua, Ching-Yen Tsai, Hsueh-Wen Chang, Sheung-Fat Ko, Cheuk-Kwan Sun, Hon-Kan Yip.   

Abstract

BACKGROUND AIMS: We hypothesized that the long-term therapeutic effect of combined sildenafil and bone marrow-derived endothelial progenitor cells (BMDEPCs) on monocrotaline (MCT)-induced rat pulmonary arterial hypertension (PAH) is superior to either treatment alone.
METHODS: Male Sprague-Dawley rats (n = 40) were equally divided into normal controls, MCT (65 mg/kg, subcutaneously) only, MCT + sildenafil (25 mg/kg/day, orally), MCT + BMDEPCs (2.0 × 10(6) autologous cells, intravenously) and MCT + sildenafil+ BMDEPCs. BMDEPCs and sildenafil were given on day 21 after MCT administration. Animals were sacrificed by day 90 after MCT administration.
RESULTS: The apoptotic (caspase 3, Bax) and inflammatory (tumor necrosis factor-α, matrix metalloproteinase-9) biomarkers in right ventricle and lung and pulmonary expressions of fibrotic biomarkers (transforming growth factor-β, p-Smad3) and connexin 43 protein were lower in monotherapy groups (i.e., MCT + sildenafil and MCT + BMDEPCs) and further decreased in normal controls and combined treatment groups (i.e., MCT + sildenafil + BMDEPCs) compared with untreated animals (i.e., MCT only) (all P < 0.01). Expressions of anti-fibrotic biomarkers (bone morphogenetic protein-2, p-Smad1/5) and numbers of alveolar sacs and arterioles in lung were higher in monotherapy groups and further increased in normal controls and combined treatment groups compared with untreated animals (all P < 0.005). In right ventricle, connexin 43 and α-myosin heavy chain (MHC) expressions were higher in the monotherapy groups and further elevated in normal controls and combined treatment groups compared with untreated animals, whereas β-MHC exhibited the opposite pattern (all P < 0.01). Right ventricular systolic pressure and weight were lower in the monotherapy animals and further reduced in normal controls and combined treatment groups compared with untreated animals (all P < 0.0001).
CONCLUSIONS: Combined therapy with BMDEPCs and sildenafil was superior to either treatment alone in attenuating rodent MCT-induced PAH.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321332     DOI: 10.1016/j.jcyt.2012.09.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  14 in total

1.  Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rieko Yoshiyuki; Telma Mary Nakata; Toshiharu Fukayama; Lina Hamabe; Hsu Huai-Che; Shuji Suzuki; Noboru Machida; Ryuji Fukushima; Ryou Tanaka
Journal:  J Med Ultrason (2001)       Date:  2013-08-24       Impact factor: 1.314

Review 2.  Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series).

Authors:  Arnoud van der Laarse; Christa M Cobbaert; Soban Umar
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

3.  Human induced pluripotent stem cell-derived mesenchymal stem cell therapy effectively reduced brain infarct volume and preserved neurological function in rat after acute intracranial hemorrhage.

Authors:  Kuan-Hung Chen; Kun-Chen Lin; Christopher Glenn Wallace; Yi-Chen Li; Pei-Lin Shao; John Y Chiang; Pei-Hsun Sung; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

4.  Effect of early administration of lower dose versus high dose of fresh mitochondria on reducing monocrotaline-induced pulmonary artery hypertension in rat.

Authors:  Tien-Hung Huang; Sheng-Ying Chung; Sarah Chua; Han-Tan Chai; Jiunn-Jye Sheu; Yi-Ling Chen; Chih-Hung Chen; Hsueh-Wen Chang; Meng-Shen Tong; Pei-Hsun Sung; Cheuk-Kwan Sun; Hung-I Lu; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

5.  Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.

Authors:  Eric G Schmuck; Timothy A Hacker; David A Schreier; Naomi C Chesler; Zhijie Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-01       Impact factor: 4.733

Review 6.  Stem cell therapy for pulmonary arterial hypertension: An update.

Authors:  Qiwei Wilton Sun; Zhongjie Sun
Journal:  J Heart Lung Transplant       Date:  2022-03-06       Impact factor: 13.569

7.  Effective protection against acute respiratory distress syndrome/sepsis injury by combined adipose-derived mesenchymal stem cells and preactivated disaggregated platelets.

Authors:  Chih-Hung Chen; Yung-Lung Chen; Pei-Hsun Sung; Cheuk-Kwan Sun; Kuan-Hung Chen; Yi-Ling Chen; Tien-Hung Huang; Hung-I Lu; Fan-Yen Lee; Jiunn-Jye Sheu; Sheng-Ying Chung; Mel S Lee; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-07-17

8.  Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis.

Authors:  Fan-Yen Lee; Kuan-Hung Chen; Christopher Glenn Wallace; Pei-Hsun Sung; Jiunn-Jye Sheu; Sheng-Ying Chung; Yung-Lung Chen; Hung-I Lu; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsin-Ju Chiang; Hsueh-Wen Chang; Mel S Lee; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-07-11

Review 9.  Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension.

Authors:  France Dierick; Julien Solinc; Juliette Bignard; Florent Soubrier; Sophie Nadaud
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

10.  Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?

Authors:  Fanny Loisel; Bastien Provost; François Haddad; Julien Guihaire; Myriam Amsallem; Bojan Vrtovec; Elie Fadel; Georges Uzan; Olaf Mercier
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.